Risk factors

The company faces unique risks from being a low-volume battery purchaser dependent on concentrated third-party manufacturers and suppliers. Rapid growth, complex product manufacturing, and variable order intake threaten future profitability and scaling efforts.

Medical-device regulation, product quality, lawsuits, and manufacturing or sterilization failures dominate the risk section.

This being Azenta's initial risk filing, it lacks prior-year comparisons. The risk section is dominated by supply chain vulnerabilities, international trade and currency risks, customer concentration, and intellectual property exposure.

This company faces high customer concentration with Home Depot and Walmart, significant supply chain reliance on China, and $1.2 billion in total debt.

Interest rate sensitivity and net interest income dependence dominate Capitol Federal Financial's risk profile. Commercial loan expansion and technology reliance create significant operational risks. Regulatory oversight by the OCC, FRB, and FDIC heavily restricts business activities.

Enanta requires substantial additional funding to advance its preclinical and clinical pipelines in viral and inflammatory diseases. Its key revenue source depends entirely on AbbVie commercializing the MAVYRET/MAVIRET hepatitis C regimen. The company faces intense competition across therapeutic areas like RSV, CSU, AD, COVID-19, and HBV from major pharmaceutical firms.

SemiLEDs faces ongoing net losses and cash requirements, relying heavily on LED component sales and key geographic markets.

Aerospace and defense sales dominate Moog's business, representing 73% of 2024 revenue. Defense spending and military programs like FLRAA drive key segments.

Sanmina relies on a concentrated group of top customers and international manufacturing operations for its electronics and cloud solutions.

Scotts depends heavily on Home Depot and Lowe’s, which generated 48% of fiscal 2024 net sales.

Analog Devices relies heavily on independent distributors, accounting for 58% of fiscal 2024 revenue. The company maintains significant manufacturing and international operations across Ireland, the Philippines, Thailand, and Malaysia. Outstanding indebtedness stands at approximately $7.6 billion, including short-term commercial paper.

Clinical stage risks and reliance on unproven drug candidates dominate the filing.